{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:17:23Z","timestamp":1791919043763,"version":"4.3.4"},"reference-count":41,"publisher":"American Association for Cancer Research (AACR)","issue":"5","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Genes encoding components of the PI3K\u2013AKT\u2013mTOR signaling axis are frequently mutated in cancer, but few mutations have been characterized in MTOR, the gene encoding the mTOR kinase. Using publicly available tumor genome sequencing data, we generated a comprehensive catalog of mTOR pathway mutations in cancer, identifying 33 MTOR mutations that confer pathway hyperactivation. The mutations cluster in six distinct regions in the C-terminal half of mTOR and occur in multiple cancer types, with one cluster particularly prominent in kidney cancer. The activating mutations do not affect mTOR complex assembly, but a subset reduces binding to the mTOR inhibitor DEPTOR. mTOR complex 1 (mTORC1) signaling in cells expressing various activating mutations remains sensitive to pharmacologic mTOR inhibition, but is partially resistant to nutrient deprivation. Finally, cancer cell lines with hyperactivating MTOR mutations display heightened sensitivity to rapamycin both in culture and in vivo xenografts, suggesting that such mutations confer mTOR pathway dependency.<\/jats:p>\n                  <jats:p>Significance: We report that a diverse set of cancer-associated MTOR mutations confer increased mTORC1\/2 pathway activity and that cells harboring these mutations are highly sensitive to rapamycin in culture and in vivo. These findings are clinically relevant as the MTOR mutations characterized herein may serve as biomarkers for predicting tumor responses to mTOR inhibitors. Cancer Discov; 4(5); 554\u201363. \u00a92014 AACR.<\/jats:p>\n                  <jats:p>See related commentary by Rejto and Abraham, p. 513<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 495<\/jats:p>","DOI":"10.1158\/2159-8290.cd-13-0929","type":"journal-article","created":{"date-parts":[[2014,3,14]],"date-time":"2014-03-14T21:59:50Z","timestamp":1394834390000},"page":"554-563","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":419,"title":["A Diverse Array of Cancer-Associated\n                    <i>MTOR<\/i>\n                    Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity"],"prefix":"10.1158","volume":"4","author":[{"given":"Brian C.","family":"Grabiner","sequence":"first","affiliation":[{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Nardi","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u0131van\u00e7","family":"Birsoy","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Possemato","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang","family":"Shen","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumi","family":"Sinha","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Jordan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Beck","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Sabatini","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"},{"name":"Authors' Affiliations: 1Whitehead Institute for Biomedical Research; 2Howard Hughes Medical Institute and Department of Biology, MIT; 3Broad Institute of Harvard and MIT; 4The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge; 5Department of Pathology, Massachusetts General Hospital Cancer Center; and 6Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2014,5,1]]},"reference":[{"key":"2022060623424941000_bib1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"2022060623424941000_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022060623424941000_bib3","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1038\/onc.2010.28","article-title":"Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer","volume":"29","author":"Sato","year":"2010","journal-title":"Oncogene"},{"key":"2022060623424941000_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"2022060623424941000_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2022060623424941000_bib6","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2022060623424941000_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"2022060623424941000_bib8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2022060623424941000_bib9","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer","volume":"39","author":"Forbes","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"2022060623424941000_bib10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature08987","article-title":"International network of cancer genome projects","volume":"464","author":"Hudson","year":"2010","journal-title":"Nature"},{"key":"2022060623424941000_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet"},{"key":"2022060623424941000_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/path.4203","article-title":"Complete genomic landscape of a recurring sporadic parathyroid carcinoma","volume":"230","author":"Kasaian","year":"2013","journal-title":"J Pathol"},{"key":"2022060623424941000_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat Genet"},{"key":"2022060623424941000_bib14","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/ng.2329","article-title":"De novo somatic mutations in components of the PI3K\u2013AKT3\u2013mTOR pathway cause hemimegalencephaly","volume":"44","author":"Lee","year":"2012","journal-title":"Nat Genet"},{"key":"2022060623424941000_bib15","doi-asserted-by":"crossref","first-page":"e43369","DOI":"10.1371\/journal.pone.0043369","article-title":"Novel somatic mutations to PI3K pathway genes in metastatic melanoma","volume":"7","author":"Shull","year":"2012","journal-title":"PLoS ONE"},{"key":"2022060623424941000_bib16","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060623424941000_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4137\/JGE.S12583","article-title":"Exome sequencing reveals de novo germline mutation of the mammalian target of rapamycin (MTOR) in a patient with megalencephaly and intractable seizures","volume":"2","author":"Smith","year":"2013","journal-title":"J Genomes Exomes"},{"key":"2022060623424941000_bib18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"2022060623424941000_bib19","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1073\/pnas.0608510104","article-title":"Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells","volume":"104","author":"Urano","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060623424941000_bib20","doi-asserted-by":"crossref","first-page":"18443","DOI":"10.1073\/pnas.0508988102","article-title":"The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells","volume":"102","author":"Zhao","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060623424941000_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrc2109","article-title":"Hyperactive Ras in developmental disorders and cancer","volume":"7","author":"Schubbert","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2022060623424941000_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Network TCGAR","year":"2013","journal-title":"Nature"},{"key":"2022060623424941000_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"2022060623424941000_bib24","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","article-title":"DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival","volume":"137","author":"Peterson","year":"2009","journal-title":"Cell"},{"key":"2022060623424941000_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/cimm.1995.1100","article-title":"Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma","volume":"163","author":"Dumont","year":"1995","journal-title":"Cell Immunol"},{"key":"2022060623424941000_bib26","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.molmed.2012.05.007","article-title":"Amino acids and mTORC1: from lysosomes to disease","volume":"18","author":"Efeyan","year":"2012","journal-title":"Trends Mol Med"},{"key":"2022060623424941000_bib27","doi-asserted-by":"crossref","first-page":"e36775","DOI":"10.1371\/journal.pone.0036775","article-title":"Coupling of glucose deprivation with impaired histone H2B monoubiquitination in tumors","volume":"7","author":"Urasaki","year":"2012","journal-title":"PLoS ONE"},{"key":"2022060623424941000_bib28","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1158\/0008-5472.CAN-08-4806","article-title":"Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry","volume":"69","author":"Hirayama","year":"2009","journal-title":"Cancer Res"},{"key":"2022060623424941000_bib29","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/carcin\/bgs203","article-title":"Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA","volume":"33","author":"Gulhati","year":"2012","journal-title":"Carcinogenesis"},{"key":"2022060623424941000_bib30","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1126\/science.1232044","article-title":"A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1","volume":"340","author":"Bar-Peled","year":"2013","journal-title":"Science"},{"key":"2022060623424941000_bib31","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-11-2123","article-title":"PIK3CA\/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors","volume":"18","author":"Meric-Bernstam","year":"2012","journal-title":"Clini Cancer Res"},{"key":"2022060623424941000_bib32","doi-asserted-by":"crossref","first-page":"e37431","DOI":"10.1371\/journal.pone.0037431","article-title":"Genotype-dependent efficacy of a dual PI3K\/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas","volume":"7","author":"Shoji","year":"2012","journal-title":"PLoS ONE"},{"key":"2022060623424941000_bib33","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/0008-5472.CAN-11-2195","article-title":"Rapamycin resistance is linked to defective regulation of Skp2","volume":"72","author":"Totary-Jain","year":"2012","journal-title":"Cancer Res"},{"key":"2022060623424941000_bib34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12122","article-title":"mTOR kinase structure, mechanism and regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"2022060623424941000_bib35","first-page":"79","article-title":"Phosphatidylinositol 3-kinase: the oncoprotein","volume":"347","author":"Vogt","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"2022060623424941000_bib36","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"2022060623424941000_bib37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.urolonc.2013.07.010","article-title":"Precision medicine for metastatic renal cell carcinoma","volume":"32","author":"Sonpavde","year":"2014","journal-title":"Urol Oncol"},{"key":"2022060623424941000_bib38","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-13-0353","article-title":"Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib","author":"Wagle","year":"2014  13","journal-title":"Cancer Discov"},{"key":"2022060623424941000_bib39","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.1021\/jm101144f","article-title":"Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benz o[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer","volume":"53","author":"Liu","year":"2010","journal-title":"J Med Chem"},{"key":"2022060623424941000_bib40","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1073\/pnas.95.4.1432","article-title":"RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1","volume":"95","author":"Burnett","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060623424941000_bib41","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1126\/science.1157535","article-title":"The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1","volume":"320","author":"Sancak","year":"2008","journal-title":"Science"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/4\/5\/554\/1845123\/554.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/4\/5\/554\/1845123\/554.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T19:43:22Z","timestamp":1654544602000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/4\/5\/554\/4465\/A-Diverse-Array-of-Cancer-Associated-MTOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,1]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,1]]},"published-print":{"date-parts":[[2014,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-13-0929","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22529654","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529654.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529624","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529636","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529648","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529648.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529630","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529642","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529645.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529639.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529636.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529633.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529630.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529633","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529645","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529657","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529624.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529627.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529627","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529639","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529651","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529642.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546005.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546005","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529651.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529657.v1","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.3410\/f.718315323.793522111","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,1]]}}}